+91 789 2456 581 | info@nckpharma.com

Pharma News

Keep updating your pharma knowledge
6 Apr 2017

Takeda – Finch Therapeutics drug development & commercialization deal for IBD molecule

/
Posted By
/
Comments0
/

Takeda is paying Finch Therapeutics $10 million upfront for exclusive, global rights to develop and commercialize the latter’s inflammatory bowel disease (IBD) candidate, FIN-524, together with rights to follow-on products for IBD indications.

Under terms of the deal, Finch will be eligible for undisclosed development, regulatory, and commercialization milestones, plus future tiered royalties. The firms have written-in the option to extend their collaboration to other, related indications.

FIN-524 is a live microbial cocktail that Massachusetts-based Finch is taking through preclinical development for treating ulcerative colitis. The candidate has been developed using the firm’s human-first discovery platform, which uses machine learning algorithms to analysis clinical datasets from ulcerative colitis patients who have undergone fecal transplantation, and identify promising therapeutic strains.

Leave a Reply

Scale up your Pharma knwledge to Next Level with our Free Content

Case studies & Caselets
Simulation based learning
Online self competency assessment tests 

etc.